MARKET

NMTR

NMTR

9 Meters Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.695
+0.030
+1.80%
Opening 14:38 02/26 EST
OPEN
1.670
PREV CLOSE
1.665
HIGH
1.820
LOW
1.590
VOLUME
3.84M
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
0.3701
MARKET CAP
343.50M
P/E (TTM)
-1.7647
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
3 Penny Stocks To Buy Under $3 Right Now But Are They Worth It?
Feb 24, 2021 (Penny Stocks via COMTEX) -- 3 Penny Stocks to Watch in the Second Half of February As we get started on another week of February, investors...
Penny Stocks · 1d ago
4 Penny Stocks To Add To Next Week's Watch List
Penny Stocks · 1d ago
Are Penny Stocks Worth It? 4 Biotech Stocks To Watch This Week
Feb 24, 2021 (Penny Stocks via COMTEX) -- Penny Stocks To Watch Right Now As Biotech Industry Grows It can be difficult to know if the penny stocks on your...
Penny Stocks · 1d ago
Best Penny Stocks To Buy? 2 Analysts Like These 3 Cheap Stocks
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Say These Are Penny Stocks To Buy But Do You Agree? We've discussed analysts' ratings and penny stocks...
Penny Stocks · 1d ago
3 Penny Stocks To Buy Under $2 & Analysts Have Targets Up To 367%
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Say These Are Penny Stocks To Buy; Do You Agree? We talk a lot about penny stocks for obvious reasons. But...
Penny Stocks · 1d ago
Thinking about buying stock in Gevo, Remark Holdings, 9 Meters Biopharma, Vertex Energy, or Grupo Supervielle?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, MARK, NMTR, VTNR, and SUPV.
PR Newswire - PRF · 02/19 14:31
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16)
Benzinga · 02/17 12:26
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11)
Benzinga · 02/11 12:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NMTR. Analyze the recent business situations of 9 Meters Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NMTR stock price target is 4.250 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 60.75M
% Owned: 29.98%
Shares Outstanding: 202.65M
TypeInstitutionsShares
Increased
14
10.15M
New
32
21.78M
Decreased
5
1.10M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.83%
Key Executives
Chairman/Chief Executive Officer/Director
Sandeep Laumas
Chief Financial Officer/Chief Accounting Officer
Edward Sitar
Other
Patrick Griffin
Director
Michael Constantino
Director
John Temperato
Vice President - Operations
Marc Matejka
Independent Director
Lorin Johnson
Independent Director
Roy Proujansky
Independent Director
Mark Sirgo
  • Dividends
  • Splits
  • Insider Activity
No Data
About NMTR
9 Meters Biopharma, Inc., formerly Innovate Biopharmaceuticals, Inc., is a gastrointestinal platform company. The Company is focused on developing treatments for patients with rare disorders and unmet needs. Its pipeline includes drug candidates for short bowel syndrome and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis.

Webull offers kinds of 9 Meters Biopharma Inc stock information, including NASDAQ:NMTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NMTR stock methods without spending real money on the virtual paper trading platform.